Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:approves |
gptkb:2009
gptkb:FDA |
| gptkbp:available_on |
generic version
|
| gptkbp:class |
alpha-2 adrenergic agonist
|
| gptkbp:clinical_trial |
pediatric studies
safety studies ADHD treatment studies long-term efficacy studies |
| gptkbp:contraindication |
recent myocardial infarction
severe coronary insufficiency conduction disturbances hypersensitivity to guanfacine |
| gptkbp:dosage_form |
extended-release tablet
|
| gptkbp:duration |
varies by patient
|
| gptkbp:financial_support |
take as prescribed
report any severe side effects do not stop abruptly |
| gptkbp:form |
gptkb:tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
Intuniv
|
| gptkbp:ingredients |
guanfacine
|
| gptkbp:interacts_with |
gptkb:beer
CNS depressants MAO inhibitors antihypertensives |
| gptkbp:is_monitored_by |
blood pressure
heart rate |
| gptkbp:manufacturer |
gptkb:Shire_Pharmaceuticals
|
| gptkbp:marketed_as |
gptkb:Australia
gptkb:Canada gptkb:European_Union gptkb:United_States |
| gptkbp:related_to |
gptkb:Tenex
|
| gptkbp:requires |
gptkb:true
|
| gptkbp:route_of_administration |
oral
|
| gptkbp:side_effect |
fatigue
nausea low blood pressure irritability drowsiness constipation dry mouth bradycardia |
| gptkbp:storage |
room temperature
away from moisture away from light |
| gptkbp:strength |
1 mg
2 mg 3 mg 4 mg |
| gptkbp:used_for |
treatment of ADHD
|
| gptkbp:bfsParent |
gptkb:Shire_plc
|
| gptkbp:bfsLayer |
5
|